2626 Stock Overview
Xiamen Kingdomway Group Company engages in the manufacturing and sale of the nutrition and health products in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Xiamen Kingdomway Group Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.34 |
| 52 Week High | CN¥22.35 |
| 52 Week Low | CN¥10.71 |
| Beta | 0.94 |
| 1 Month Change | -6.32% |
| 3 Month Change | -6.84% |
| 1 Year Change | -38.81% |
| 3 Year Change | -63.95% |
| 5 Year Change | -16.10% |
| Change since IPO | 82.35% |
Recent News & Updates
Shareholder Returns
| 2626 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.9% | -1.5% | -0.4% |
| 1Y | -38.8% | -16.0% | -17.6% |
Return vs Industry: 002626 underperformed the CN Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 002626 underperformed the CN Market which returned -17.8% over the past year.
Price Volatility
| 2626 volatility | |
|---|---|
| 2626 Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 002626 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002626's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 2,907 | Bin Jiang | www.kingdomway.com |
Xiamen Kingdomway Group Company engages in the manufacturing and sale of the nutrition and health products in China and internationally. It offers its products under the Doctor’s Best, Zipfizz, Kingdomway, Labrada, Prosupps, Maikon, and Jinlexin brands. The company was formerly known as Xiamen Jindawei Vitamin Co., Ltd.
Xiamen Kingdomway Group Company Fundamentals Summary
| 2626 fundamental statistics | |
|---|---|
| Market cap | CN¥8.14b |
| Earnings (TTM) | CN¥151.62m |
| Revenue (TTM) | CN¥3.03b |
53.7x
P/E Ratio2.7x
P/S RatioIs 2626 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2626 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.03b |
| Cost of Revenue | CN¥1.97b |
| Gross Profit | CN¥1.06b |
| Other Expenses | CN¥908.14m |
| Earnings | CN¥151.62m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 0.25 |
| Gross Margin | 35.03% |
| Net Profit Margin | 5.01% |
| Debt/Equity Ratio | 13.6% |
How did 2626 perform over the long term?
See historical performance and comparison